From Endpoints to Discovery, see how Ozette’s platform assesses assay precision, specimen stability, and the effect of sample storage on immune cells.
This year at CYTO, Ozette showcased “An automated approach to high-parameter spectral flow cytometry assay validation using a novel AI/ML platform to assess the precision and stability of predefined biomarker endpoints in the context of a 48-color pan-immune profiling panel.” If you weren’t able to catch us at the conference or want to take a closer look, download the event poster here.
Applying Ozette Discovery™ to CITE-seq data to identify predictors of disease.
Methods such as CITE-seq simultaneously measure RNA and protein expression at a single cell level, but the protein expression data is frequently underutilized. Download our preprint to learn how we harness Ozette Discovery™ to achieve instantaneous in silico sorting of granular cell phenotypes, enabling identification of COVID-19-associated cell populations and precise RNA-seq profiling in mixed samples.
Effective comparison of single-cell embedding visualizations.
At ISMB 2023, Ozette’s Trevor Manz lead a lively panel on effective comparison of single-cell embedding visualizations. To better understand the approach, challenges, and conclusions, learn more by downloading the event poster here.
Automated gating and antigen-specific T cells subset discovery using FAUST and COMPASS on ICS data.
At ISMB 2022, Ozette Computational Biologist Malisa Smith, and Ozette Co-Founder Evan Greene, PhD VP of Quantitative Methods discussed automated gating and antigen-specific T cells subset discovery using FAUST and COMPASS on ICS data as well as how they reanalyzed a published Intracellular Cytokine Staining (ICS) dataset. Download the poster to learn more about their presentation.
Discovering data transformations for effective visualization of single-cell embeddings.
At ISMB 2022, Ozette’s Fritz Lekschas, PhD, Head of Visualization Research lead a fascinating discussion about data transformations for effective visualization of single-cell embeddings. If you weren’t able to attend, take a look at this beautiful and though provoking work.
From assay to endpoints, see how Ozette’s proprietary processes deliver results.
Recently, at CYTO 2023, we showcased how Ozette Endpoints™ and Ozette Discovery™ technologies leverage Artificial Intelligence and Machine Learning to deliver robust computational analysis pipelines and allow for rapid insights into complex high-dimensional data. View process details, methods, and case study examples in our detailed conference poster.
Vaccination induces HIV broadly neutralizing antibody precursors in humans.
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial…
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses.
The engineered outer domain germline targeting version 8 (eOD-GT8) 60-mer nanoparticle was designed to prime VRC01-class HIV-specific B cells that would need to be matured, through additional heterologous immunizations, into B cells that are able to produce broadly neutralizing antibodies. CD4 T cell help will be critical for the development of such high-affinity neutralizing antibody responses. Thus, we assessed the induction and epitope specificities of the vaccine-specific T cells…
Ozette’s AI in the battle against COVID-19.
In-depth immune profiling reveals a T regulatory signature that correlates with COVID-19 disease severity, an important finding as Treg cells are potential targets for treatment strategies and fighting severe disease.
Going beneath the surface of skin cancer.
We investigated our AI’s ability to predict treatment response to PD1 inhibiting immunotherapy in Merkel cell carcinoma and melanoma. We benchmarked our algorithmic approach against conventional analysis.